0.68
Schlusskurs vom Vortag:
$0.77
Offen:
$0.7231
24-Stunden-Volumen:
2.42M
Relative Volume:
1.06
Marktkapitalisierung:
$77.93M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.4121
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-22.87%
1M Leistung:
-33.98%
6M Leistung:
-78.21%
1J Leistung:
-90.30%
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
0.68 | 77.93M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
2023-01-06 | Herabstufung | Stifel | Buy → Hold |
2023-01-06 | Herabstufung | Truist | Buy → Hold |
2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-12-15 | Eingeleitet | Goldman | Sell |
2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
2022-07-28 | Eingeleitet | Needham | Hold |
2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
2021-12-07 | Eingeleitet | Cowen | Outperform |
2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
2021-04-26 | Fortgesetzt | Jefferies | Buy |
2021-02-26 | Eingeleitet | BofA Securities | Buy |
2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | Bestätigt | Mizuho | Buy |
2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
2019-11-12 | Eingeleitet | SunTrust | Buy |
2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
2019-10-01 | Eingeleitet | Stifel | Buy |
2019-08-09 | Eingeleitet | BTIG Research | Buy |
2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
2019-06-13 | Eingeleitet | Mizuho | Buy |
2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
2019-05-31 | Eingeleitet | Guggenheim | Buy |
2019-05-24 | Fortgesetzt | Citigroup | Buy |
2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
2018-11-05 | Eingeleitet | Jefferies | Buy |
2018-08-01 | Eingeleitet | Citigroup | Buy |
2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance
Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World
Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World
Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register
Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks
Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada
Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Nasdaq
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating - Investing.com India
Y Intercept Hong Kong Ltd Invests $58,000 in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics: Q4 Earnings Snapshot - mySA
Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses - TipRanks
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - Marketscreener.com
Fate Therapeutics shares rise as Q4 revenue tops estimates By Investing.com - Investing.com South Africa
Fate Therapeutics shares rise as Q4 revenue tops estimates - Investing.com
Fate Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics, Inc Q4 Loss Misses Estimates - Nasdaq
Fate Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 04:13 pm EST - Marketscreener.com
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating - Defense World
FATE stock touches 52-week low at $1.03 amid sharp annual decline - Investing.com
Fate Therapeutics (FATE) Expected to Announce Earnings on Monday - MarketBeat
Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average PT from Analysts - Armenian Reporter
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):